-transparent.png){kind=logo}
alpha-Adrenergic agonists with pulmonary vasoconstrictor activity could potentiate or prolong the bronchodilator action of a locally administered beta-adrenergic agonist by decreasing transpulmonary absorption of the compound. Results of studies using the alpha-agonist oxymetazoline and the beta-agonist orciprenaline (metaproterenol) showed that the combination of oxymetazoline [0.3 microgram] with orciprenaline (3 micrograms) offered no potency advantage and only a small duration advantage over orciprenaline alone in antagonizing a histamine-induced bronchospasm in guinea pigs. Higher doses (10 and 30 micrograms) of oxymetazoline caused bronchoconstriction when given alone and inhibited the bronchodilator action of orciprenaline. The relevance of these findings for human asthmatics hyperresponsive to the bronchoconstrictor action of alpha-agonists is discussed.
R W Chapman, and
W Kreutner
July 1995,
Indian journal of physiology and pharmacology,
R W Chapman, and
W Kreutner
December 1971,
Acta allergologica,
R W Chapman, and
W Kreutner
March 1955,
Revue de pathologie generale et de physiologie clinique,
R W Chapman, and
W Kreutner
August 1993,
The Journal of veterinary medical science,
R W Chapman, and
W Kreutner
January 2004,
Annals of clinical and laboratory science,
R W Chapman, and
W Kreutner
October 1981,
Bratislavske lekarske listy,
R W Chapman, and
W Kreutner
May 1971,
Lille medical : journal de la Faculte de medecine et de pharmacie de l'Universite de Lille,
R W Chapman, and
W Kreutner
January 1965,
Folia allergologica,
R W Chapman, and
W Kreutner
September 1967,
The Journal of pharmacy and pharmacology,
R W Chapman, and
W Kreutner
January 1983,
Farmakologiia i toksikologiia,
